WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SF 2959

Legislative bill overview

SF 2959 extends Minnesota's prohibition on manufacturers interfering with eligible institutions' access to drugs under the federal 340B program. The 340B program allows hospitals, clinics, and other covered entities to purchase outpatient drugs at discounted prices. This bill prevents pharmaceutical manufacturers from blocking or restricting these entities' ability to access those negotiated discounts.

Why is this important

The 340B program helps safety-net hospitals and community health centers reduce drug costs, enabling them to serve uninsured and low-income patients more affordably. Manufacturers have used various tactics (like refusing to sell to certain wholesalers or requiring restrictive contracts) to limit program participation, effectively raising costs for vulnerable populations. This legislation protects access to one of the few price-control mechanisms available in the U.S. pharmaceutical market.

Potential points of contention

  • Pharmaceutical industry opposition: Manufacturers may argue the restrictions limit their ability to prevent program abuse or control their distribution channels
  • Scope and enforceability: Questions about how violations are defined, detected, and punished without creating administrative burdens
  • Market competition concerns: Whether prohibiting manufacturer practices affects broader drug pricing dynamics or simply shifts costs between different buyer categories

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.